Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1Advanced Cancer 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × prexasertib × Clear all
NCT02555644 2019-02-15

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Eli Lilly and Company

Phase 1 Completed
70 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡